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ABSTRACT
Objectives: Acetylcholine M (muscarinic) receptors are possibly involved in tardive dyskinesia
(TD). The authors tried to verify this hypothesis by testing for possible associations between two
muscarinic receptor genes (CHRM1 and CHRM2) polymorphisms and TD in patients with
schizophrenia.
Methods: A total of 472 patients with schizophrenia were recruited. TD was assessed cross-sec-
tionally using the Abnormal Involuntary Movement Scale. Fourteen allelic variants of CHRM1 and
CHRM2 were genotyped using Applied Biosystems amplifiers (USA) and the MassARRAY System
by Agena Bioscience.
Results: The prevalence of the rs1824024GG genotype of the CHRM2 gene was lower in TD
patients compared to the group without it (v2¼ 6.035, p¼ 0.049). This suggested that this
genotype has a protective effect for the development of TD (OR¼ 0.4, 95% CI: 0.19–0.88). When
age, gender, duration of schizophrenia and dosage of antipsychotic treatment were added as
covariates in regression analysis, the results did not reach statistical significance.
Conclusions: This study did identify associations between CHRM2 variations and TD; the results
of logistic regression analysis with covariates suggest that the association is, however, likely to
be secondary to other concomitant factors.
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The extrapyramidal side effects (EPSs) of antipsychotic
drugs (akathisia, parkinsonism, dystonia and tardive dys-
kinesia (TD)) are caused by dysfunctions of the cortico–-
striato–[.]–thalamo–cortical regulatory circuits (Loonen
and Ivanova 2013). The vast majority of the neurons of
the corpus striatum (caudate, putamen, and accumbens)
belong to gamma-amino butyric acid (GABA)-ergic
medium-sized spiny projection neurons (MSNs) (95%),
or to three types of GABA-ergic interneurons ( 4%).
Only 1–2% (approximately) of the striatal nerve cells are
cholinergic interneurons, but still these giant, aspiny
neurons make the striatum the largest cholinergic
nucleus of the central nervous system as they ramify
extensively and send projections widely throughout this
ganglion (Lim et al. 2014; Gonzales and Smith 2015).
Almost all striatal cholinergic synapses belong to one of
these cholinergic interneurons, which are believed to be
the analogues of tonically active neurons identified by in
vivo recordings in the putamen of primates (Deffains
and Bergman 2015). This means that these neurons
show spontaneous activity, in which this basal activity
can be modulated up- and downward by synaptic input.
Acetylcholine stimulates both striatal nicotinic and
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muscarinic receptors. Muscarinic receptors are more
widely spread and can be divided into excitatory M1
class (M1, M3, M5) and inhibitory M2 class (M2, M4)
receptors (Goldberg et al. 2012; Lim et al. 2014).
Blocking these muscarinic receptors non-selectively with
anticholinergic drugs such as trihexyphenidyl (Cyclodol)
(Bolden et al. 1992) is common procedure in the treat-
ment of antipsychotic drug-induced parkinsonism and
dystonia. Concomitant (prophylactic) anticholinergic
treatment of EPSs is, however, considered to be one of
the risk factors for TD (Jankelowitz 2013), although
Altamura et al. (1990) did not find a significant associ-
ation between anticholinergic drug use and the preva-
lence of TD. On the other hand, some studies suggest
an improvement in TD with the cessation of anticholi-
nergics (Desmarais et al. 2012).
Muscarinic receptor inhibition has been associated
with a variety of neuropsychiatric disorders, including
delirium (Hshieh et al. 2008; Campbell et al. 2009),
dementia (Campbell et al. 2009; Jiang et al. 2014),
depression (Drevets et al. 2013; Jeon et al. 2015), bipo-
lar disorder (Jeon et al. 2015; Van Enkhuizen et al.
2015) and schizophrenia (McKinzie and Bymaster 2012).
In particular, gene polymorphisms in the M1 receptor
(CHRM1) have been found to be associated with psychi-
atric symptoms and cognitive function in schizophrenic
patients (Liao et al. 2003), in the M4 receptor (CHRM4)
with schizophrenia (Scarr et al. 2013), and in the M2
receptor (CHRM2) with autonomic nervous system
activity in patients with schizophrenia on high-dose
antipsychotics (Miyauchi et al. 2016).
The present study aims to test for associations
between the muscarinic receptor (CHRM1 and CHRM2)
gene polymorphisms and the prevalence of TD in 472
ethnic Russian patients with schizophrenia.
Methods
Patients
This study was carried out in accordance with the
Code of Ethics of the World Medical Association
(Declaration of Helsinki 1975, revised in Fortaleza,
Brazil, 2013), established for experiments involving
humans. We recruited patients from three psychiatric
hospitals located in the Tomsk, Kemerovo, and Chita
oblasts (regions) of Siberia, Russia. Each patient pro-
vided written informed consent after the study was
approved (protocol N63/7.2014) by the Local Bioethics
Committee of the Mental Health Research Institute.
The inclusion criteria were a clinical diagnosis of
schizophrenia, according to the International Statistical
Classification of Diseases and Related Health Problems,
10th Revision (ICD-10: F20), and being aged between
18 and 75 years old. Exclusion criteria were non-
Caucasian physical appearance (e.g., Mongoloid,
Buryats, or Khakassians), pregnancy, any relevant phys-
ical disorder, including organic brain disorders (e.g.,
epilepsy or Parkinson’s disease), or any relevant
pharmacological withdrawal symptoms. To compare
antipsychotic medications, all drug doses taken at the
time of investigation were converted into chlorpro-
mazine equivalents (CPZeq; Andreasen et al. 2010).
A total of 194 patients received typical antipsychotics
(of which haloperidol was the most often used: 115
patients; chlorpromazine, 44 patients (as well as chlor-
prothixene, zuclopenthixol, thioridazine and pericia-
zine)). A total of 172 patients received atypical
antipsychotics (mainly risperidone, clozapine and quetia-
pine, and to a lesser extent olanzapine, sertindole, pali-
peridone, and amisulpride), and 83 patients received
combined therapy. Patients were assessed once for the
presence or absence of dyskinesia according to the
abnormal involuntary movement scale (AIMS) (Loonen
and Van Praag 2007; Loonen et al. 2000, 2001). The
AIMS scores were transformed into a binary form (pres-
ence or absence of dyskinesia) with Schooler and Kane’s
criteria (1982). Schooler–Kane criteria require: (i) at least
3months of cumulative exposure to neuroleptics; (ii) the
absence of other conditions that might cause involun-
tary movements and (iii) at least moderate dyskinetic
movements in one body area (3 on AIMS) or mild dys-
kinetic movements in two body areas (2 on AIMS).
DNA analysis
Blood samples were obtained from each participant
and used for DNA isolation by a standard phenol-
chloroform method. Genotyping was performed with-
out any knowledge of the patient’s clinical status.
Genotyping was carried out on six polymorphic var-
iants of gene CHRM1 (rs2075748, rs544978, rs2067477,
rs2067479, rs2186410 and rs542269) and eight poly-
morphic variants of gene CHRM2 (rs2061174,
rs324650, rs2350780, rs1824024, rs7810473, rs2350786,
rs324640 and rs1378650) by real-time PCR using
Applied Biosystems amplifiers (USA) in the Laboratory
of Molecular Genetics and Biochemistry of Mental
Health Research Institute (Tomsk), and with the use of
The MassARRAY System by Agena Bioscience in the
Laboratory of Genetics of the University of Groningen.
DNA concentrations were measured with a Thermo
Scientific NanoDrop 8000 UV-Vis Spectrophotometer.
Possibly relevant SNPs were selected according to the
literature data on associations with schizophrenia and
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other mental disorders (Cohen-Woods et al. 2009;
Jagannathan et al. 2010; Michel and Teitsma 2012;
Miyauchi et al. 2016) and programme LD TAG SNP
Selection (TagSNP).
Statistical analysis
Statistical analyses were performed using SPSS for
Windows, v. 17. The Mann–Whitney test was used to com-
pare qualitative traits and the v2 test was used for cat-
egorical traits. Genotype prevalence was checked for
concordance with the expectation under Hardy–Weinberg
equilibrium using the v2-test. Allele and genotype fre-
quencies were compared using the v2-test and Fisher’s
exact test, if necessary. The differences were considered
statistically significant at P< 0.05. The size of the effect of
genetic polymorphism on the risk of TD was estimated
using odds ratio (OR) and 95% confidence intervals (CIs).
Also, logistic regression with adjustment for covariates
was applied to test for association between the SNPs and
TD. Age, gender, duration of schizophrenia and dosage of
antipsychotic treatment were used as covariates since
they have been shown to have statistically significant
effects on the risk of TD. No essential multicollinearity was
observed between the covariates (variance inflation fac-
tors ranged from 1.2 to 2.3). Experiment-wise permuta-
tions were used to address the multiple testing issue as
described in the paper Churchill and Doerge (2011).
Results
A total of 472 patients with schizophrenia was
recruited after obtaining informed consent, of whom
449 patients were included for subsequent study due
to their fulfilling the criterion of receiving the anti-
psychotic treatment for more than 3 months.
According to the other predefined criteria, 121
patients suffered from TD (Table 1).
The mean age of patients with dyskinesia was signifi-
cantly higher than the age of the comparison group
and the duration of schizophrenia was significantly lon-
ger than in patients without TD.
The prevalence of genotypes of studied genes did not
deviate from expectation under the Hardy–Weinberg equi-
librium, except for rs544978, rs2067477 and rs2186410 in
the CHRM1 gene. These SNPs were therefore excluded
from analysis.
Table 2 presents the genotype and allele prevalence
in patients with and without TD; a statistically significant
lower frequency of the rs2061174C allele of the CHRM2
gene was found in patients with TD in comparison to
the group without TD (v2¼ 3.84, P¼ 0.05).
The frequency of the rs1824024GG genotype of the
CHRM2 gene was marginally significantly lower in TD
patients compared to the group without it (v2¼ 6.035,
P¼ 0.049) suggesting its protective effect on the devel-
opment of TD (OR¼ 0.40, 95% CI: 0.19–0.88).
When age, gender, duration of schizophrenia and
dosage of antipsychotic treatment in CPZeq were
added as covariate in logistic regression analysis, how-
ever, the results did not reach statistical significance
(permutation p> 0.05).
Discussion
In this study we found a borderline statistical signifi-
cant association between two variants of the muscar-
inic M2 receptor (CHRM2) gene and the risk of
developing TD: rs2061174 and rs1824024. However,
logistic regression analysis showed that this observa-
tion may also be related to well-known risk factors of
TD, such as sex, age, duration of the disease and the
dosages of antipsychotics (Solmi et al. 2018). All these
factors were associated with TD in our study.
SNPs rs2061174 and rs1824024 are located in the
intron; their functional role is not fully understood,
but they have been demonstrated to be significantly
associated with risk for major depression, alcoholism
and cognitive abilities (Wang et al. 2004; Luo et al.
2005, 2007; Thongket et al. 2016).
CHRM2 has a relative low abundancy within the
striatum in comparison to CHRM1 and CHRM4 (Lim
et al. 2014). CHRM2 is a primarily inhibitory autorecep-
tor of cholinergic interneurons and moreover inhibits
glutamatergic thalamostriatal and corticostriatal termi-
nals on direct and indirect pathway MSNs (Goldberg
et al. 2012; Lim et al. 2014). As cholinergic interneur-
ons show spontaneous activity, inactivity of CHRM2
can, in theory, lead to TD. Inactivity of M2 receptors
would increase cholinergic stimulation of M1 and M4
Table 1. Characteristics of the studied patient groups.
Patients without TD (n¼ 328) Patients with TD (n¼ 121) P value
Gender: Male, n (%) 152 (46.3%) 71 (58.7%) 0.027
Female, n (%) 176 (53.7%) 50 (41.3%)
Age, years 37 [31; 48] 48 [37.5; 58] <0.001
Age of onset, years 24 [20; 30] 25 [20; 32] 0.974
Duration of disease, years 11 [5; 18] 20 [12; 29.5] <0.001
CPZeq 396 [200; 750] 500 [286.2; 750] 0.021
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receptors on MSNs and excitatory nicotinergic recep-
tors at glutamatergic and dopaminergic terminals.
Less-active CHRM2 would increase the release of glu-
tamate from thalamostriatal and corticostriatal termi-
nals on MSNs. As inhibitory CHRM4 are less abundant
on indirect pathway MSNs, these neurons would be
more vulnerable to glutamatergic (over)stimulation
than direct pathway MSNs. We have previously sug-
gested that neurotoxicity of indirect pathway MSN
could explain the development of TD (Loonen and
Ivanova 2013). Increased glutamatergic activity and/or
augmented sensitivity to glutamatergic activation
could result in greater likelihood of reaching neuro-
toxic effects. However, this would be unrelated to the
usage of anticholinergic drugs, since these non-select-
ively block all subtypes of muscarinic receptors
(Bolden et al. 1992).
The CHRM4 is particularly interesting in this respect
as this inhibitory muscarinic receptor is unevenly distrib-
uted between direct and indirect pathway MSN.
Table 2. Genotype distribution in patients with TD.
Gene Polymorphic variant Genotypes/Alleles With TD Without TD
OR
v2 Pvalue 95% CI
CHRM1 rs2075748 GG 80 (66.7%) 223 (68.4%) 0.92 0.59–1.44 0.179 0.915
GA 36 (30.0%) 94 (28.8%) 1.06 0.67–1.67
AA 4 (3.3%) 9 (2.8%) 1.21 0.37–4.02
G 0.817 0.828 0.92 0.63–1.36 0.16 0.69
A 0.183 0.172 1.08 0.74–1.59
rs2067479 TT 0 (0.0%) 0 (0.0%) 2.7 0.05–136.61 1.311 0.252
TC 7 (5.8%) 32 (9.8%) 0.57 0.24–1.32
CC 114 (94.2%) 295 (90.2%) 1.77 0.76–4.12
T 0.029 0.049 0.58 0.25–1.33 1.7 0.19
C 0.971 0.951 1.73 0.75–3.97
rs542269 CC 5 (4.5%) 14 (4.6%) 0.97 0.34–2.77 1.07 0.586
CT 39 (35.1%) 123 (40.6%) 0.79 0.50–1.25
TT 67 (60.4%) 166 (54.8%) 1.26 0.81–1.96
C 0.221 0.249 0.85 0.59–1.23 0.72 0.4
T 0.779 0.751 1.17 0.81–1.69
CHRM2 rs2061174 TT 60 (49.6%) 144 (44.0%) 1.25 0.82–1.90 5.633 0.06
TC 53 (43.8%) 134 (41.0%) 1.12 0.74–1.71
CC 8 (6.6%) 49 (15.0%) 0.4 0.18–0.88
T 0.715 0.645 1.38 1.00–1.90 3.84 0.05
C 0.285 0.355 0.73 0.53–1.00
rs324650 AA 27 (22.5%) 79 (24.2%) 0.91 0.55–1.49 0.171 0.918
AT 59 (49.2%) 159 (48.8%) 1.02 0.67–1.54
TT 34 (28.3%) 88 (27.0%) 1.07 0.67–1.70
A 0.471 0.486 0.94 0.70–1.26 0.17 0.68
T 0.529 0.514 1.06 0.79–1.43
rs2350780 AA 53 (43.8%) 142 (43.4%) 1.02 0.67–1.55 1.467 0.48
AG 56 (46.3%) 139 (42.5%) 1.17 0.77–1.77
GG 12 (9.9%) 46 (14.1%) 0.67 0.34–1.32
A 0.669 0.647 1.11 0.81–1.51 0.4 0.53
G 0.331 0.353 0.9 0.66–1.24
rs1824024 GG 8 (6.7%) 49 (15.0%) 0.4 0.19–0.88 6.035 0.049
GT 55 (45.8%) 125 (38.3%) 1.36 0.89–2.08
TT 57 (47.5%) 152 (46.6%) 1.04 0.68–1.58
G 0.296 0.342 0.81 0.59–1.11 1.69 0.19
T 0.704 0.658 1.24 0.90–1.71
rs7810473 AA 44 (37.6%) 99 (35.0%) 1.12 0.72–1.75 0.292 0.864
AG 51 (43.6%) 131 (46.3%) 0.9 0.58–1.38
GG 22 (18.8%) 53 (18.7%) 1 0.58–1.74
A 0.594 0.581 1.05 0.77–1.44 0.11 0.74
G 0.406 0.419 0.95 0.70–1.29
rs2350786 GG 60 (54.5%) 155 (51.2%) 1.15 0.74–1.78 1.198 0.549
GA 44 (40.0%) 122 (40.3%) 0.99 0.63–1.54
AA 6 (5.5%) 26 (8.6%) 0.61 0.25–1.54
G 0.745 0.713 1.18 0.83–1.68 0.85 0.36
A 0.255 0.287 0.85 0.60–1.20
rs324640 GG 37 (30.8%) 103 (31.5%) 0.97 0.62–1.52 0.038 0.981
GA 56 (46.7%) 153 (46.8%) 1 0.65–1.51
AA 27 (22.5%) 71 (21.7%) 1.05 0.63–1.73
G 0.542 0.549 0.97 0.72–1.31 0.04 0.85
A 0.458 0.451 1.03 0.77–1.39
rs1378650 CC 33 (29.5%) 76 (25.0%) 1.25 0.77–2.03 1.933 0.38
CT 50 (44.6%) 159 (52.3%) 0.74 0.48–1.14
TT 29 (25.9%) 69 (22.7%) 1.19 0.72–1.96
C 0.518 0.512 1.03 0.75–1.39 0.03 0.87
T 0.482 0.488 0.97 0.72–1.32
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The CHRM4 rs2067482 polymorphism was associ-
ated with an increased risk of schizophrenia identified
by sequencing this gene from the brains of 76 people
with the disorder, and from 74 people with no history
of psychiatric disorders (Scarr et al. 2013).
The study of gene–gene interaction between mus-
carinic receptors and glutamate receptors and the
relationship between CHRM4 gene and TD, possibly
through the pathogenesis of schizophrenia, therefore,
merits further investigation.
A limitation of our study might be the usage of
anticholinergic drug (trihexyphenidyl) and drugs with
anticholinergic effects, including certain antipsychotics
(Bolden et al. 1992) and that of atypicals, affecting the
prevalence of TD through other types of receptor
interactions. Patients receiving monotherapy or com-
bination therapy with different typical and atypical
antipsychotics may have a higher risk of developing
TD (like typical antipsychotics) or be associated with
lower TD risk (like clozapine).
Two advantages of our study are the large patient
numbers and the careful diagnosis of TD according to
Schooler and Kane’s criteria (1982).
It can be concluded that, in our patient population,
a rather weak association between the prevalence of
TD and two variants of the CHRM2 gene were found,
which lost significance when other possibly contribu-
ting factors accounted for.
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